MAGEA3 and head and neck squamous cell carcinoma: A randomised Phase 2 study investigating MAGEA3 multipeptide vaccine GL-0817 (Biropepimut-S) in combination with GM-CSF and polyICLC for the prevention of recurrence in HLA-A2 patients with HNSCC is currently ongoing (NCT02873819, Table 2).